Gene Therapy
Alterations in Respiration II
Classifying Matter by Composition
Altered States of Awareness
Alterations in Blood Pressure
Composite Bodies
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 31, 2026

Separation and Differential Characterization of Gut Microbial Extracellular Vesicles in Salt-Sensitive Rats under High-Salt Diet Conditions
Published on: June 6, 2025
Ilana Katz Sand1, Yunjiao Zhu1, Achilles Ntranos1
1Department of Neurology (I.K.S., A.N., R.B., Y.B.), Department of Neuroscience (Y.Z., P.C.), and Department of Genetics & Genomic Sciences, Icahn Institute for Genomics & Multiscale Biology (J.C.C.), Icahn School of Medicine at Mount Sinai; Department of Neurology (E.C., E.C.-H., S.S., B.A.C.C., S.E.B.), Weill Institute for Neurosciences, University of California, San Francisco; E.C. is now with Universities Space Research Association, Space Biosciences Division, NASA Ames Research Center, Moffett Field, CA; Department of Pediatrics (J.D., R.K.), Department of Computer Science & Engineering (R.K.), and Center for Microbiome Innovation (R.K.), University of California, San Diego; and Neuroscience Initiative (P.C.), Advanced Research Science Center at the Graduate Center of the City University of New York.
Disease-modifying therapies like glatiramer acetate (GA) and dimethyl fumarate (DMF) alter gut microbiota in multiple sclerosis (MS) patients. These changes impact key metabolic pathways, suggesting new therapeutic avenues for MS.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: